EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti‐GDF‐15 Antibody‐Based Combination Therapies

Danna M Breen iD, Stephanie Joaquim, Brianna LaCarubba Paulhus, Donald Bennett, Barbara Bernardo, Susie Collins, Ryan M Esquejo, Ja Young Kim-Muller, Laura Lin, Matthew Peloquin, Zhidan Wu, Shuxi Qiao und 3 weitere

Journal of Cachexia, Sarcopenia and Muscle · 2026

DOI: 10.1002/jcsm.70312 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Danna M Breen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Cachexia, Growth Differentiation Factor 15, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a recent Phase 2 trial in patients with cancer cachexia, the anti‐GDF‐15 antibody ponsegromab resulted in increased body weight, appetite, muscle mass and physical activity. This study provides compelling evidence that targeting the GDF‐15 pathway may offer a viable therapeutic strategy, while raising new mechanistic questions about how GDF‐15 neutralization could be optimally integrated with other interventions to reverse the multifactorial cachexia syndrome. This series of experiments aimed to evaluate the effects of anti‐GDF‐15 antibody treatment in combination with muscle anabolic (anti‐myostatin antibody) or appetite stimulant (ghrelin receptor agonist anamorelin) modulators using mouse cancer cachexia models.

Methods

The effects of anti‐GDF‐15 monoclonal antibody alone and in combination with an anti‐myostatin antibody or anamorelin fumarate were examined in GDF‐15‐dependent (HT‐1080 and RENCA) and partially dependent (TOV21G) mouse tumour models. Comprehensive assessments included food intake, body weight, body composition (including fat, lean and muscle mass), muscle function and treadmill running. Circulating myostatin was measured in patient samples from an advanced NSCLC clinical study.

Results

Anti‐myostatin antibody treatment had limited efficacy in improving cachexia in mouse tumour models with high circulating GDF‐15 (HT‐1080 and RENCA), but improved cachexia (when combined with anti‐GDF‐15 antibody) in a tumour model with low circulating GDF‐15 levels (TOV21G). In the TOV21G model, combining anti‐myostatin and anti‐GDF‐15 antibodies led to even greater increases in body weight and hindlimb muscle mass compared with anti‐GDF‐15 antibody alone ( p < 0.001 for muscle mass); however, the increase in muscle strength and treadmill running did not reach statistical significance over monotherapy. When anamorelin was combined with anti‐GDF‐15 antibody, body weight was elevated compared with the HT‐1080 tumour‐bearing vehicle group ( p < 0.0001) but did not reach statistical significance over anti‐GDF‐15 antibody alone. Similar observations of the combination treatment were found for food intake, fat mass and gastrocnemius ( p < 0.05). Circulating myostatin was negatively correlated with weight loss in patients with cancer ( p < 0.01).

Conclusion

These data provide proof‐of‐principle that mechanistically distinct approaches targeting muscle anabolism and appetite may act additively with GDF‐15 neutralization, particularly in cancer cachexia settings with lower GDF‐15 dependence. Trial Registration: ClinicalTrials.gov identifier: NCT01360554.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCachexiaGrowth Differentiation Factor 15NeoplasmsAnimalsFemaleHumansMaleMiceCell Line, TumorDisease Models, AnimalHydrazinesMyostatinOligopeptides

Stichwörter der Autor:innen

GDF‐15cachexiaghrelinmouse tumour modelsmyostatin

Substanzen

anamorelinAntibodies, MonoclonalGrowth Differentiation Factor 15HydrazinesMyostatinOligopeptides

Autor:innen und Institutionen

  • Internal Medicine Research Unit, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Biostatistics, Early Clinical Development, Pfizer Inc, Cambridge, Massachusetts, USA.
  • Statistics, Internal Medicine Research Unit, Pfizer R&D UK Limited, Cambridge, UK.
  • Biomedicine Design, Pfizer Inc, Cambridge, Massachusetts, USA.

ORCID-Profile: Danna M Breen

Förderung

  • Pfizer

Zitieren

APA

Breen, D. M., Joaquim, S., Paulhus, B. L., Bennett, D., Bernardo, B., Collins, S., Esquejo, R. M., Kim-Muller, J. Y., Lin, L., Peloquin, M., Wu, Z., Qiao, S., Stansfield, J. C., Zhang, B. B., & Rossulek, M. I. (2026). Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti‐GDF‐15 Antibody‐Based Combination Therapies. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70312

Vancouver

Breen DM, Joaquim S, Paulhus BL, Bennett D, Bernardo B, Collins S, et al. Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti‐GDF‐15 Antibody‐Based Combination Therapies. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70312

BibTeX
@article{Breen2026,
  author = {Breen, Danna M and Joaquim, Stephanie and Paulhus, Brianna LaCarubba and Bennett, Donald and Bernardo, Barbara and Collins, Susie and Esquejo, Ryan M and Kim-Muller, Ja Young and Lin, Laura and Peloquin, Matthew and Wu, Zhidan and Qiao, Shuxi and Stansfield, John C and Zhang, Bei B and Rossulek, Michelle I},
  title = {Targeting Cancer Cachexia: A Mechanistic Evaluation of Anti‐GDF‐15 Antibody‐Based Combination Therapies},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  doi = {10.1002/jcsm.70312}
}
Kostenlos starten →